Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint

Executive Summary

Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.

Advertisement

Related Content

Galectin Offers Subgroup Approach For Struggling NASH Candidate
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Intercept's Revised NASH Trial Improves Prospects
Endpoint Selection Could Help Determine The NASH Race
Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure
Intercept’s Phase III Endpoints May Not Apply To Other Firms’ NASH Programs
Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints
Searching For Surrogate Endpoints Requires Teamwork

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel